Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-1
2006-002703-13Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of albinterferon alfa-2b in chronic hepatitis C virus infection (2 arms), sponsored by GSK. Primary endpoint: Sustained virologic response. Started Dec 2006; status: completed.
02
Drugs
albinterferon alfa-2b
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on 2006-002703-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002703-13.